Furthermore, our recent study found that for those postresectional recurred NSCLC patients who planned for adjuvant immunotherapy, dissected lymph node count ≤16 is associated with immunotherapy prognostic benefit, and this may be related to the retention of more CD8+ central memory T cells30. Here, CD8A is linked to non-small cell lung carcinoma.